Jon Congleton has been named president and CEO of Seattle-based Impel NeuroPharma. Congleton was most recently president and CEO of Nivalis Therapeutics in Boulder, CO. Impel is developing intranasal drug treatments for central nervous system disorders.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
